Company intelligence / Profile preview
NeoIndicate
Wellington, Ohio, United Statesneoindicate.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
NeoIndicate's lead imaging agent (NEO-001) and platform agents have shown rapid, highly specific binding and detection of tumor cells—including invasive GBM—in animal models. Preclinical data supports sensitive tumor cell identification for improved neurosurgical resection and potential for diagnosis, imaging (fluorescent, MRI, PET), and theranostic treatment. Human clinical trials for brain tumor imaging agents were planned for 2023. Radiopharm Theranostics has licensed development for clinical radiopharmaceutical use.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculePeptideFluorescent imaging agentMRI imaging agentPET imaging agentRadiopharmaceuticalTheranostic agent
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Case Western Reserve University (licensor, academic)Radiopharm Theranostics (exclusive radiopharma sublicensee)
Beyond the preview
Go deeper on NeoIndicate.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NeoIndicate.